scholarly article | Q13442814 |
P50 | author | George G. Netto | Q74759772 |
William B Isaacs | Q89161930 | ||
Jessica Hicks | Q96146588 | ||
Wennuan Liu | Q101050166 | ||
David M Esopi | Q114718054 | ||
Siobhan Sutcliffe | Q49392833 | ||
Angelo M De Marzo | Q56417148 | ||
Alan W Partin | Q62089936 | ||
Tamara L Lotan | Q62091289 | ||
Jianfeng Xu | Q67190177 | ||
P2093 | author name string | Misop Han | |
Ben H Park | |||
Bora Gurel | |||
Elizabeth Humphreys | |||
P2860 | cites work | Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2 | Q22253866 |
The genomic complexity of primary human prostate cancer | Q24617949 | ||
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology | Q24632651 | ||
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
Pten dose dictates cancer progression in the prostate | Q24791909 | ||
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. | Q27851411 | ||
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines | Q28256046 | ||
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
Integrative genomic profiling of human prostate cancer | Q29619905 | ||
Agarose mold embedding of cultured cells for tissue microarrays | Q30310276 | ||
PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. | Q30472730 | ||
Practical methods for tissue microarray construction. | Q30772247 | ||
Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis | Q33266259 | ||
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study | Q80166443 | ||
Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation | Q80557787 | ||
Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate | Q81000526 | ||
Natural history of progression after PSA elevation following radical prostatectomy | Q33611613 | ||
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer | Q33723651 | ||
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation | Q34109986 | ||
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. | Q34973214 | ||
Subtle variations in Pten dose determine cancer susceptibility | Q35055350 | ||
Considerations when analyzing the methylation status of PTEN tumor suppressor gene | Q35788734 | ||
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression | Q36067596 | ||
Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome | Q36847856 | ||
Pten inactivation and the emergence of androgen-independent prostate cancer. | Q36885813 | ||
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. | Q37250634 | ||
Post-translational regulation of PTEN. | Q37270440 | ||
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression | Q37383459 | ||
Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells | Q37437827 | ||
Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. | Q38467346 | ||
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate | Q39506775 | ||
A robust immunohistochemical assay for detecting PTEN expression in human tumors | Q39646962 | ||
MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). | Q39728869 | ||
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias | Q40293372 | ||
PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells | Q40508012 | ||
Is PTEN loss associated with clinical outcome measures in human prostate cancer? | Q43249619 | ||
Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene. | Q46894426 | ||
Genetic alterations in the PI3K pathway in prostate cancer. | Q47797768 | ||
PTEN/MMAC1/TEP1 involvement in primary prostate cancers. | Q47814101 | ||
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts | Q47855108 | ||
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer | Q47919199 | ||
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer | Q57240096 | ||
Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome | Q57790493 | ||
ThePTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion | Q63966367 | ||
Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer | Q73235041 | ||
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues | Q74093343 | ||
Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas | Q74418921 | ||
Analysis of PTEN and the 10q23 region in primary prostate carcinomas | Q74531155 | ||
P433 | issue | 20 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | prostate cancer | Q181257 |
P304 | page(s) | 6563-6573 | |
P577 | publication date | 2011-08-30 | |
P1433 | published in | Clinical Cancer Research | Q332253 |
P1476 | title | PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients | |
P478 | volume | 17 |
Q36887707 | A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer |
Q53842727 | A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. |
Q54409274 | Activation of mammalian target of rapamycin signaling pathway markers in minute adenocarcinoma of the prostate. |
Q26830671 | Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis |
Q37029385 | Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools |
Q33414685 | Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus |
Q37268981 | Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus |
Q55237889 | Advances in prostate cancer research models: From transgenic mice to tumor xenografting models. |
Q36610246 | An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy |
Q38833458 | Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. |
Q51033341 | Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. |
Q39634850 | Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer |
Q42119481 | Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion |
Q55399069 | Biomarkers in active surveillance. |
Q90082711 | Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial |
Q36965321 | Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression |
Q35101357 | Can we accurately report PTEN status in advanced colorectal cancer? |
Q38151298 | Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer? |
Q42356687 | Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG. |
Q63866039 | Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer |
Q36193912 | Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis. |
Q39023426 | Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease |
Q49818398 | Clinical implications of PTEN loss in prostate cancer |
Q34498069 | Clonal progression of prostate cancers from Gleason grade 3 to grade 4. |
Q30557008 | Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer |
Q37221588 | Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer |
Q37536970 | Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. |
Q89767735 | Copy number alterations are associated with metastatic-lethal progression in prostate cancer |
Q89586700 | Could the kinetin riboside be used to inhibit human prostate cell epithelial-mesenchymal transition? |
Q38042634 | Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers |
Q36724548 | Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia |
Q38774228 | DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer |
Q35873154 | Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer |
Q38160495 | Disruption of prostate epithelial differentiation pathways and prostate cancer development |
Q40544225 | Distinct expression profile of key molecules in crawling-type early gastric carcinoma |
Q37091474 | Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder |
Q43269413 | ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss: Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression. |
Q38165243 | ERG protein expression as a biomarker of prostate cancer. |
Q57281248 | Effects of Enhancer of Zeste Homolog 2 (EZH2) Expression on Brain Glioma Cell Proliferation and Tumorigenesis |
Q42673080 | Expression and prognostic significance of ELL-associated factor 2 in human prostate cancer |
Q30573750 | Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer. |
Q55689982 | Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss? |
Q39170943 | Genomic tests to guide prostate cancer management following diagnosis |
Q85804519 | High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral |
Q98945179 | High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts |
Q92289172 | HoxB13 expression in ductal type adenocarcinoma of prostate: clinicopathologic characteristics and its utility as potential diagnostic marker |
Q36753720 | Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence |
Q41657305 | Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma |
Q91669799 | If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease |
Q33642302 | Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas |
Q39307061 | Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases |
Q37080378 | In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity |
Q40919195 | In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading |
Q96126040 | Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming |
Q26752510 | Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics |
Q37082536 | Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors |
Q30381117 | Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. |
Q35854235 | Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer |
Q38134734 | Intraductal carcinoma of prostate: a comprehensive and concise review |
Q47758797 | Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery |
Q35586422 | Loss of PLZF expression in prostate cancer by immunohistochemistry correlates with tumor aggressiveness and metastasis |
Q51549809 | Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. |
Q35234584 | Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer |
Q47976701 | MSH2 Loss in Primary Prostate Cancer |
Q47829840 | MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. |
Q91661243 | Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease |
Q36199762 | Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer |
Q27005677 | Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN |
Q38280833 | Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model |
Q50133991 | Molecular Biomarkers in the Clinical Management of Prostate Cancer. |
Q27024775 | Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer |
Q36469889 | Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization |
Q42184292 | Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues |
Q34365632 | Molecular pathways and targets in prostate cancer |
Q40740686 | Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy |
Q35176084 | Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients |
Q47664729 | Mucinous and secondary tumors of the prostate |
Q27001047 | Notch signaling in prostate cancer: a moving target |
Q53550490 | Novel Assay to Detect RNA Polymerase I Activity In Vivo. |
Q36901964 | Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma |
Q41004851 | Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer |
Q38206682 | PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance |
Q38599066 | PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer |
Q39401816 | PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer |
Q36235829 | PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors |
Q38541293 | PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis. |
Q45904675 | PTEN is a protein phosphatase that targets active PTK6 and inhibits PTK6 oncogenic signaling in prostate cancer. |
Q41907553 | PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas |
Q41912121 | PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. |
Q42371556 | PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort |
Q45251986 | PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer |
Q36287422 | PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients |
Q43089446 | PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy |
Q35540013 | PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. |
Q57049913 | PTEN status assessment in the Johns Hopkins active surveillance cohort |
Q36269232 | Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance |
Q91881793 | Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort |
Q34371057 | Prevention and early detection of prostate cancer |
Q90170218 | Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues |
Q38628081 | Prognostic and predictive biomarkers in prostate cancer |
Q38184382 | Prognostic prostate tissue biomarkers of potential clinical use. |
Q42748239 | Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer |
Q36959119 | Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. |
Q35132292 | Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas |
Q38321512 | Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. |
Q37476043 | Prostate cancer: the need for biomarkers and new therapeutic targets |
Q50141035 | Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides. |
Q39044979 | Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma |
Q38779933 | Recent advances in prostate cancer pathology: Gleason grading and beyond |
Q33852664 | Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment |
Q49721870 | Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder. |
Q90253669 | Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA |
Q90029848 | Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN) |
Q61445176 | SP1 and RARα regulate AGAP2 expression in cancer |
Q53644292 | SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development. |
Q38850627 | STAT3 regulated ARF expression suppresses prostate cancer metastasis |
Q36931932 | Should Gleason 6 be labeled as cancer? |
Q38967389 | Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers |
Q42436743 | Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers |
Q51586225 | TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer. |
Q91127371 | The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status |
Q90029873 | The Challenges of Optimizing Biomarkers To Guide Clinical Decision Making |
Q57073785 | The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature |
Q91114591 | The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy |
Q38983790 | The molecular underpinnings of prostate cancer: impacts on management and pathology practice |
Q41762568 | Tracking the clonal origin of lethal prostate cancer |
Q30572057 | Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases |
Q43104641 | Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy |
Q38540198 | Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer |
Q53108923 | [Focal therapy of prostate cancer in Germany]. |
Q57848625 | deletion in luminal cells of mature prostate induces replication stress and senescence in vivo |
Q36742601 | miR-21 Is Linked to Glioma Angiogenesis: A Co-Localization Study |
Q47231171 | p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer |